XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Show more...
FAQ
X.T.L. Biopharmaceuticals 今天的股價是多少?▼
XTLB.BOATS 目前價格為 $2.49 USD,過去 24 小時下跌了 -8.12%。在圖表上更密切關注 X.T.L. Biopharmaceuticals 股票的表現。
X.T.L. Biopharmaceuticals 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,X.T.L. Biopharmaceuticals 的股票以代號 XTLB.BOATS 進行交易。
X.T.L. Biopharmaceuticals 的市值是多少?▼
今天 X.T.L. Biopharmaceuticals 的市值為 2.19B
X.T.L. Biopharmaceuticals 去年的營收是多少?▼
X.T.L. Biopharmaceuticals 去年的營收為 902,000USD。
X.T.L. Biopharmaceuticals 去年的淨利是多少?▼
XTLB.BOATS 去年的淨收益為 -2.05MUSD。
X.T.L. Biopharmaceuticals 有多少名員工?▼
截至 April 01, 2026,公司共有 10 名員工。
X.T.L. Biopharmaceuticals 位於哪個產業?▼
X.T.L. Biopharmaceuticals從事於Health Care產業。
X.T.L. Biopharmaceuticals 何時完成拆股?▼
X.T.L. Biopharmaceuticals 上次拆股發生於 March 25, 2026,比例為 1:4。
X.T.L. Biopharmaceuticals 的總部在哪裡?▼
X.T.L. Biopharmaceuticals 的總部位於 IL 的 Ramat Gan。